Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC).

Abstract

9035Background: Monoclonal antibodies against Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) have therapeutic efficacy in NSCLC. We conducted a systematic review of trials to evaluate differences in toxicity patterns of PD-1 and PD-L1 inhibitors. Methods: An electronic literature search was performed of public databases (MEDLINE, EMBASE) and conference proceedings for trials utilizing PD-1 inhibitors (nivolumab, pembrolizumab) and PD-L1 inhibitors (atezolizumab, durvalumab, avelumab) in NSCLC patients. Studies that did not report toxicities were excluded. A formal meta-analysis was conducted with Comprehensive Meta-Analysis software (Version 2.2). Clinical and demographic characteristics, response, and toxicity data were compared between the two groups. Results: Sixteen studies reported between 2013-2015 were eligible for this analysis, with a total number of 2,845 patients in the PD-1 group and 1,595 patients in the PD-L1 group evaluated for toxicities. Patient characteristics ...